Y-mAbs' rare disease drug roundly rejected by FDA AdComm over weakness of single-arm trial

A FDA advisory committee has blown a hole in Y-mAbs Therapeutics’ hopes of winning approval for its rare disease drug, delivering a damning 0-16 verdict on the question of whether the company showed its candidate improves overall survival.